Alpha Cancer Technologies
About Us
Our Products
Alpha Fetoprotein (AFP)
Immunomodulation Platform
Targeted Immuno-Oncology Platform
Pre-Clinical Studies
ACT-101 Pre-Clinical MG Studies
ACT-101 Pre-Clinical IBD Studies
ACT-901-3 Pre-Clinical IO Studies
News
Investors
Alpha Cancer Technologies
About Us
Our Products
Alpha Fetoprotein (AFP)
Immunomodulation Platform
Targeted Immuno-Oncology Platform
Pre-Clinical Studies
ACT-101 Pre-Clinical MG Studies
ACT-101 Pre-Clinical IBD Studies
ACT-901-3 Pre-Clinical IO Studies
News
Investors
CEO Dr. Igor Sherman Featured in CEOCFO Magazine
July 12, 2022
Recent Posts
Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Alpha Cancer Technologies Presentation at Gilmartin’s Private Company Showcase
Alpha Cancer Technologies (ACT) to Participate in the Gilmartin Group Private Company Showcase
Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903
Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2023 American Society of Clinical Oncology Annual Meeting